Jenny McCarthy feels '25 again' after giving up vegan diet
The 52-year-old TV star spent years avoiding animal products because she wanted to eat "clean" but it played havoc with her digestive system and left her feeling bloated and she was told to try a "carnivore" diet by a doctor who warned her she may need a colostomy bag if her bowel problems didn't clear up.
She told PEOPLE: "My bloat was so bad that it always made me feel like I was about three months pregnant.
"And I'm sorry if this is too TMI [too much information], but I was a complicated person who only went to the bathroom once every 14 days ...
"I went on the carnivore diet. I was so against it, but my doctor was like, you've tried everything but this, so you're going carnivore ...
"I've got to tell you, it saved my gut. I go to the bathroom every single day now - and it made me feel like I was 25 again."
Jenny explained she suffers from a long list of health problems including Hashimoto's disease, a leaky gut and Coeliac disease, but her new diet has helped her feel better and she's also lost weight and her skin problems have cleared up.
She added: "All of my acne has cleared up. In one month, I lost 12 to 15 pounds ... You can't half-a** it [the diet]. But if I showed you a picture of my face from even a year ago, it's so different. I didn't realize how swollen I was all the time."
It comes after Jenny previously had to deny she'd been taking the drug Ozempic to lose weight, insisting she's slimmed down naturally but used a an AirSculpt procedure to remove fat from her tummy.
She previously told Us Weekly: "As women, we hear the: 'Oh no, when you get older you're gonna get that tire on your belly. There's nothing you can do.'
"And I always thought I was kind of invincible because I was a jock in school. I'm like, 'I played every sport. I've worked out forever.
"I'm not gonna have that problem.' But no matter how much I tried to intermittent fast [to combat aging, its side effects persist].
"And I'm not an Ozempic person. I wanted a permanent solution to a targeted area with a bonus of fixing my hands - and that's what I got."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
31-07-2025
- AU Financial Review
How Ozempic's maker lost the weight loss fight
Until a year ago, Danish drugmaker Novo Nordisk was riding high. It had been first to market with an injectable diabetes treatment and the name Ozempic quickly became shorthand for new class of blockbuster weight loss drugs. But competition started to catch up, a new drug trial disappointed, shares and growth fell and its chief executive departed in May. Then this week a major profit warning knocked more than €60 billion ($106 billion) off its value. The company also announced that senior executive Maziar Mike Doustdar would become the new CEO.
Perth Now
30-07-2025
- Perth Now
Lance Bass: 'It was a blessing to develop diabetes'
Lance Bass says getting diabetes was 'a blessing in disguise'. The NSYNC singer was first diagnosed with Type 2 diabetes during the COVID pandemic but it was later changed to Type 1.5, otherwise known as latent autoimmune diabetes of adults (LADA) and he believes the disease has made him healthier. He told TMZ: 'You know what, it was actually a blessing to develop diabetes later in life because it has made me super healthy. I feel great, better than I ever have, so hopefully I can encourage people out there to take better care of themselves.' He added a warning: 'Kids don't eat all that sugar.' LADA is similar to Type 1 diabetes, where the pancreas stops producing insulin, but develops slowly in adults over the age of 30. Lance, 46, previously admitted it had been "really hard" to keep his condition under control at first. He told PEOPLE: "I developed diabetes during COVID, and I'm really trying to figure out how to control that. I'm definitely conscious of my eating now. "I'm learning what you can eat, when you can eat, when you take your insulin - and all that has just been really hard lately." Lance - who has three-year-old twins Alexander and Violet with husband Michael Turchin - has put a huge focus on his health since he received his diagnosis. He shared: "The older I get, the more I know I have to take care of my body. So I work out when I can. "Exercising is so key right now, but it's hard for me because of my schedule to get to a gym. So I do have a nice set-up at my house and I get 15 minutes here, 20 minutes there. "The biggest thing that I've learned is to drink tons and tons of water. You think you're drinking too much water, [but] you need to drink even more than that."
Sydney Morning Herald
30-07-2025
- Sydney Morning Herald
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.
